Clinical Trials Logo

Peritoneal Dialysis Complication clinical trials

View clinical trials related to Peritoneal Dialysis Complication.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06350552 Completed - Clinical trials for End Stage Renal Disease

Prevalence of Postural Abnormalities in Dialysis Patients

Start date: April 28, 2024
Phase:
Study type: Observational

The goal of this observational study is to investigate and compare the prevalence of forward head , hyper kyphosis and balance in hemodialysis and peritoneal dialysis patients. The main questions it mains to answer are: What is the prevalence of forward head posture in hemodialysis and peritoneal dialysis patients? What is the prevalence of hyper kyphosis in hemodialysis and peritoneal dialysis patients? Is there any relation between postural abnormalities and physical function in hemodialysis and peritoneal dialysis patients? Participants will answer 2 questionnaires and will do some functional tests.

NCT ID: NCT05797181 Completed - Sarcopenic Obesity Clinical Trials

The Effect Of Medical Nutritional Therapy On Patients With Sarcopenic Obesity Receiving Peritoneal Dialysis Treatment

Start date: February 7, 2023
Phase: N/A
Study type: Interventional

In this study, it was aimed to evaluate the effectiveness of medical nutrition therapy to be applied to patients with sarcopenic obesity receiving peritoneal dialysis treatment by measuring anthropometric measurements and blood parameters.

NCT ID: NCT04923295 Completed - Clinical trials for Peritoneal Dialysis Complication

The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

Patients with average or high average peritoneal glucose transport status be included in the study as mentioned in the inclusion and exclusion criteria. The change in peritoneal glucose transport will be evaluated before and after one month treatment with 10 mg of Dapagliflozin. Peritoneal Equilibration Test (PET) test for patients before and after Dapagliflozin use and volume status of patients as measured by ultrafiltration from peritoneal dialysis exchanges. The aim of the trial is to determine whether dapagliflozin can decrease glucose absorption from peritoneal fluid and reduce plasma glucose absorption from the PD fluid and thus improve ultrafiltration with a reduction in intraperitoneal glucose exposure

NCT ID: NCT04797195 Completed - Clinical trials for Kidney Failure, Chronic

Improving Care for Peritoneal Dialysis Patients With the CKD-PD App

Start date: December 13, 2021
Phase: N/A
Study type: Interventional

Managing the hydration status in patients undergoing peritoneal dialysis (PD) is a key task for nephrologists in Thailand that is made difficult due to lack of timely access to hydration metrics including weight, blood pressure, and ultrafiltration volume. This research project aims to improve the monitoring of hydration status in PD patients from a bimonthly, in-clinic review of a handwritten log-book to a smart phone based app (CKD-PD) with digitized data that allows for near real time monitoring hydration abnormalities, thereby creating the opportunity for earlier treatment of overhydration. The investigators hypothesize that use of the CKD-PD will improve early treatment of overhydration, and potentially reduce the incidence of complications, hospitalizations, and mortality in PD patients.

NCT ID: NCT04302649 Completed - Clinical trials for Peritoneal Dialysis Complication

Dialysate Temperature in Peritoneal Dialysis

TPD
Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Patients on continuous ambulatory peritoneal dialysis (PD) are encouraged to warm dialysate to 37°C before peritoneal infusion; main international PD guidelines do not provide specific recommendation, and patients generally warm dialysate batches partially or do not warm them at all. Warming of dialysate is a time-consuming procedure, not free from potential risks (i.e. degradation of glucose), and should be justified by a clear clinical benefit. The investigators designed a single blind randomized controlled trial where PD patients were randomized to receive a peritoneal equilibration test either with dialysate at a controlled temperature of 37°C (intervention group) or with dialysate warmed with conventional methods (control group). Primary end-point was a higher peritoneal creatinine clearance in patients in the intervention group.

NCT ID: NCT04176627 Completed - Clinical trials for Peritoneal Dialysis Complication

Assessing Fluid Status of Peritoneal Dialysis Patients With Assistance of Lung Ultrasound

Fluid-PLUS
Start date: December 2, 2019
Phase:
Study type: Observational

- As studied previously, lung congestion is very prevalent however usually asymptomatic in dialysis patients. Fluid overload is associated with hospitalizations, worse cardiovascular outcomes and mortality in PD patients. - The clinical exam is the only tool used currently to monitor volume status of PD patients, and has been found to have poor sensitivity and specificity for lung congestion compared to lung ultrasound. In current practice, patients are seen and examined monthly at their home dialysis units by the nurses. The nephrologist separately examines the patient monthly, possibly days to weeks after the nurse visit, and potentially only quarterly with the use of telehealth visits. - Lung ultrasound is a relatively simple and cheap tool to assess for lung congestion, with little inter-operator variability and good reproducibility. - There are limited studies of lung ultrasound in peritoneal dialysis, and none in the United States. Lung ultrasound may be useful as an objective measure of lung congestion in patients without signs or symptoms of fluid overload. Aims of this study - This study aims to determine the prevalence of subclinical fluid overload in peritoneal dialysis patients. - The investigators aim to determine the added benefit of lung ultrasound to standard clinical practice of fluid management in PD patients. - The investigators aim to assess the association of patient characteristics with lung congestion. - The investigators also aim to assess the agreement between nurse physical exam and lung ultrasound for fluid overload.

NCT ID: NCT04046263 Completed - Hyperphosphatemia Clinical Trials

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

Prospective pilot study to determine if changing the phosphate binder to sucroferric oxyhydroxide for for 6 months improves disordered mineral metabolism and nutrition status in peritoneal dialysis patients.

NCT ID: NCT03759002 Completed - Clinical trials for Cardiovascular Diseases

Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.

Start date: February 1, 2016
Phase:
Study type: Observational

Cardiovascular disease (CVD) is the major risk factor for death in end stage renal diseases (ESRD). Approximately 80% of ESRD patients have some degrees of left ventricular abnormalities at initiation of dialysis. Carotid intima media thickness (CIMT) has been widely accepted as an useful marker to assess CVD in ESRD children. In addition, cardiac mechanics parameters are used to evaluate cardiac function more precisely. However, measuring CIMT and cardiac mechanics parameters are expensive and difficult to perform as a routine method. Mean platelet volume (MPV) is a hematological index which shows the size of platelets. Uremic state causes inflammatory condition that affects MPV. Previous studies on people with normal renal function have shown that this parameter can also have association with CVD. However the data in children with ESRD is scarce. The aim of this study is to find a simple hematologic marker to use regularly in ESRD children finding patients at risk of CVD. Therefore, we will investigate the relationship between mean platelet volume and CIMT and cardiac mechanic parameters in children with ESRD.

NCT ID: NCT03569410 Completed - Malnutrition Clinical Trials

The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients

Start date: October 2016
Phase: N/A
Study type: Interventional

This study is a prospective open label clinical trial comparing serum albumin levels and total protein intake in the peritoneal dialysis patient population. A total of 60 patients were enrolled, 16 chose to be in the natural food group and 44 in the supplement group. 4 were lost to follow-up in the supplement group leading to an n of 40. Both groups were educated by dietitians on how to increase their protein intake to a goal of 1.4g/kg/day. The groups were followed for 3 months with protein intake calculated according to the patient's food diaries. Patient demographics and characteristics were compared in both groups.

NCT ID: NCT03458819 Completed - Clinical trials for Peritoneal Dialysis Complication

EMT in Peritoneal Dialysis Patients

Start date: March 20, 2018
Phase:
Study type: Observational

Approximately 10-11% of end stage kidney disease patients worldwide utilize peritoneal dialysis (PD) as their method of renal replacement therapy. Over time, the peritoneal membrane often undergoes anatomic and functional changes due to the process of epithelial to mesenchymal transition (EMT). EMT is characterized by increases in pro-inflammatory and pro-angiogenic cytokines. In this process, the mesothelial cells lining the peritoneal membrane are denuded and change their morphology to one more closely resembling fibroblasts. These fibroblasts invade the submesothelial zone of the peritoneal membrane resulting in marked fibrosis, and the pro-angiogenic cytokines cause an increase in neovascularization. Jointly, these processes culminate in impaired function of the peritoneal membrane and often limit the duration of effective PD therapy. In vitro studies in cultured human peritoneal mesothelial cells (HPMCs) and in vivo studies in rodent models of PD have demonstrated that the use of active Vitamin D receptor agonists or statins may attenuate this process of EMT. These are both classes of drugs that are commonly in use by patients on PD. The investigators goal is to determine whether either or both of these drugs might attenuate the process of EMT in patients performing PD.